ArticleMolecular genetics & genomic medicine2026
Monoallelic SH2B1 Variants in Neurodevelopmental Disorders: Phenotypic Expansion and Functional Characterization of Rare Variants.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSH2B1 encodes an adaptor protein involved in metabolic regulation and body-weight control. Although SH2B1 haploinsufficiency is a recognized contributor to obesity in 16p11.2 deletion syndrome, the relationship between rare monoallelic SH2B1 variants and neurodevelopmental disorders (NDDs) remains poorly characterized.
methodsWe analyzed genetic and clinical data from a cohort of individuals with NDDs. The identified rare SH2B1 variants were evaluated using bioinformatic tools and structural modeling. Functional consequences were assessed in vitro through analyses of protein expression, subcellular localization, and extracellular signal-regulated kinase (ERK) pathway activation via EGF stimulation assays.
resultsFive individuals carrying rare monoallelic SH2B1 variants presented with syndromic NDDs, including developmental delay, intellectual disability, autism spectrum disorder, dysmorphic features, and hyperphagia. Whole-exome sequencing identified five heterozygous SH2B1 variants, including three missense variants (c.52C>G, p.Leu18Val; c.696A>T, p.Arg232Ser; c.1141C>T, p.Pro381Ser) and two truncating variants (c.90_91delTG, p.Cys30Ter; c.121_130dup, p.Arg44LeufsTer30); four of these arose de novo, whereas c.696A>T (p.Arg232Ser) was maternally inherited. The individual carrying the maternally inherited p.Arg232Ser variant presented with elevated BMI and hyperphagia. In overexpression assays, truncating variants showed reduced protein expression and abnormal subcellular localization, whereas missense variants retained comparable protein levels but showed increased EGF-induced ERK phosphorylation in vitro, suggesting altered ERK signaling responses.
conclusionsThis study further delineates the clinical spectrum associated with rare monoallelic SH2B1 variants in individuals with NDDs. Functional analyses suggest variant-specific effects on protein expression, subcellular localization, and ERK signaling responses. These findings support the consideration of SH2B1 in genetic analyses of NDDs, particularly in individuals with co-occurring metabolic abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.